Skip to content

Peri-Implant Soft Tissue Integration in Humans: Influence of Material

Peri-Implant Soft Tissue Integration in Humans: Influence of Material

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05805033
Enrollment
40
Registered
2023-04-07
Start date
2023-09-22
Completion date
2024-10-01
Last updated
2024-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects

Brief summary

The purpose of this study is to compare the mucointegration of 2 types of surface roughness of zirconia abutments with titanium. The surface roughness will be machined and ultra-polished.

Detailed description

After being informed about the study and potential risks, all participants give written informed consent and eligibility for study entry. The day of the surgery, patients will be randomized in machined zirconia or ultra-polished zirconia. After 8 weeks of healing, biopsy are separated in two groups according to the removal: * if the abutment come together with the surrounding soft tissues, it goes for a non decalcified histology for histometric measurements to determine the dimensions of biological width (sulcus depth, epithelial and connective adhesion) * if the abutment come separate of the surrounding tissue, the soft tissue goes for immunohistochemistry to analyse pro-inflammatory cells and vascularisation and the abutment for SEM analysis to calculate the percentage of adhesion of the cells on the abutment

Interventions

OTHERMucointegration

Placement of abutment on a dental implant to study mucointegration

Sponsors

Centre Hospitalier Universitaire de Liege
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Participants have to voluntarily sign the informed consent form before any study related action * Patients aged 18 or over * Patients with one or more missing teeth in the maxillary or mandible area, seeking implant therapy * Men/women * Patients in good systemic health (ASA I/ II) and no contraindication for oral surgical interventions * Patients requiring a replacement of missing teeth; the tooth at the implant site(s) must have been extracted or lost at least 12 weeks before the date of implantation * At least 3 mm of fibrous mucosa in the bucco-lingual dimension * Full mouth plaque score (FMPI) lower than or equal to 25% * At least a diameter of 4 mm for the implant (regular diameter)

Exclusion criteria

* Autoimmune disease requiring medical treatment * Medical conditions requiring prolonged use of steroids * Use of Bisphosphonates intravenously or more than 3 years of oral use * Infection (local or systemic) - patients with gingivitis or active local infection will undergo a medical treatment prior to the entrance to the study, and each individual will be evaluated for suitability; in case of a systemic infection, the evaluation will be based on medical anamneses, and if necessary, a patient will be referred to relevant medical tests * Current pregnancy or breastfeeding women * Alcoholism or chronical drug abuse * Immunocompromised patients * Uncontrolled diabetes * Smokers * Prisoners * Implant's diameter under 4 mm (narrow implant) * Conditions or circumstances, in the opinion of the investigator, which would prevent completion of the study or interference with analysis of study results, such as history of non-compliance, or unreliability

Design outcomes

Primary

MeasureTime frameDescription
Histomorphometry8 weeks of healingHeight measure of biological width (sulcus depth, epithelial and connective adhesion)
Immunohistology8 weeks of healingAnalysis of the pro-inflammatory cells and vascularisation of the soft tissue + analysis of the percentage of cells adhesion on the abutment

Countries

Belgium

Contacts

Primary ContactClémentine Canuel, MsD
clementine.canuel@hotmail.fr+33679097264

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026